Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

NCT03816319 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03816319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 12, 2025
Completion date
October 24, 2026
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome with excess blasts, recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, recurrent myelodysplastic syndrome/acute myeloid leukemia, refractory acute myeloid leukemia, refractory myelodysplastic syndrome, refractory myelodysplastic syndrome/acute myeloid leukemia